Navigation Links
GNC Unveils Study Results for First and Only Nitric Oxide Product Clinically Proven to Improve Physical Performance at NSCA Conference in Las Vegas
Date:7/13/2009

LAS VEGAS, July 13 /PRNewswire-FirstCall/ -- GNC, the leading global specialty retailer of nutritional products, announced today clinical results for the first and only nitric oxide product, Amplified Maxertion N.O., proven to demonstrate a delay in the onset of neuromuscular fatigue. The key findings were unveiled at the National Strength and Conditioning Association (NSCA) conference in Las Vegas, NV.

GNC's Amplified Maxertion N.O.(TM) was shown to increase power output at the onset of neuromuscular fatigue by an average of 20% and improve physical performance by helping athletes push past their normal point of exhaustion. This product is designed to increase nitric oxide levels in the body causing a hemodilation effect which expands blood vessels, allowing more blood, oxygen and nutrients to flow to muscles.

"This is truly groundbreaking research that has resulted in the delivery of a truly novel and clinically-validated product to the industry," said Guru Ramanathan, SVP Technology and Product Innovation for GNC. "Using advanced technology and ingredients, this is the first Nitric Oxide enhancing product to demonstrate significant athletic performance effects that are relevant and meaningful to all types of athletes."

The purpose of the double-blind placebo-controlled study was to examine the effects of daily administration of arginine-based supplements on the physical working capacity at the fatigue threshold (PWC(FT)). The PWC(FT) test estimates the highest power output that can be maintained without neuromuscular evidence of fatigue.

Using a cycle ergometer (stationary bicycle), all subjects performed an incremental test to exhaustion prior to supplementation and after four weeks of supplementation. Key study findings demonstrate significant mean increases in PWC(FT) for the 1.5 gm (22.4%) and 3.0 gm (18.8%) supplement groups, but no change for the placebo group (-1.6%).

'/>"/>
SOURCE GNC
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Oregon Tourism Commission Unveils New Online Customer Service Training Program
2. NeoVista Unveils 18-month Data on Novel Wet AMD Therapy at Retina Society Meeting
3. Schering-Plough Unveils Top-Line Study Results for SAPHRIS(TM) (asenapine) Demonstrating Efficacy in Long-Term Schizophrenia Relapse Prevention
4. OmegaGenesis Unveils Novel Nanotechnology Platform With Broad Biomedical Applications
5. Ferring Pharmaceuticals Unveils Six-Month Efficacy Data for EUFLEXXA(R) for the Treatment of Osteoarthritis Knee Pain
6. Boehringer Ingelheim Unveils Diabetes Pipeline
7. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
8. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
9. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
10. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
11. Multiple Myeloma Research Consortium (MMRC) Partners with Novartis to Advance Phase II Study of Deacetylase Inhibitor
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... , Jan. 15, 2014 Most osteoporosis patients want ... a recent online survey* sponsored by Mission Pharmacal Company. ... National Osteoporosis Foundation online support community, revealed that 74 ... that comes in a form other than a pill ...
(Date:1/15/2014)... 2014  Novation, the leading health care supply chain expertise, ... reseller (VAR) national contracts that expand its portfolio to ... lower costs. These include manufacturer product and service agreements, ... and ongoing IT consulting support. New ...
(Date:1/15/2014)... , Jan. 15, 2014  Humberto C. Antunes,  Galderma  ... Award" from the Journal of Drugs in Dermatology ... Clinical Conference (ODAC). The event is January 17-20, 2014, at the ... . The ODAC is a ...
Breaking Medicine Technology:Mission Pharmacal Conducts Online Survey of Osteoporosis Patients 2Mission Pharmacal Conducts Online Survey of Osteoporosis Patients 3New Novation Information Technology VAR Contracts Offer Significant Savings to Hospitals 2Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 2Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 3Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 4
... , FRIMLEY, England, December 8 , ... Treatment Effectiveness,in the Trial, in Patients With Newly-Diagnosed Disease(1) , ... the Disease on nilotinib (300mg Twice-Daily and 400mg Twice-Daily) Than on,imatinib 400mg ... Only a Small Number of Patients,Discontinued Due to Adverse Events(1) , ...
... ... , ... - Will Use BrainTrack,s College Campus Data to Enhance Elsevier Evolve,Website Registrations ... technical and,medical information products and services, and BrainTrack,( http://www.braintrack.com ), the widely referenced ...
Cached Medicine Technology:Novartis Tasigna(R) (nilotinib) Trial Shows Superior Results to Glivec(R) (imatinib) in Newly Diagnosed, Chronic Phase Chronic Myeloid Leukaemia 2Novartis Tasigna(R) (nilotinib) Trial Shows Superior Results to Glivec(R) (imatinib) in Newly Diagnosed, Chronic Phase Chronic Myeloid Leukaemia 3Novartis Tasigna(R) (nilotinib) Trial Shows Superior Results to Glivec(R) (imatinib) in Newly Diagnosed, Chronic Phase Chronic Myeloid Leukaemia 4Novartis Tasigna(R) (nilotinib) Trial Shows Superior Results to Glivec(R) (imatinib) in Newly Diagnosed, Chronic Phase Chronic Myeloid Leukaemia 5Novartis Tasigna(R) (nilotinib) Trial Shows Superior Results to Glivec(R) (imatinib) in Newly Diagnosed, Chronic Phase Chronic Myeloid Leukaemia 6Elsevier Selects BrainTrack Directory as Supplier of College Data 2Elsevier Selects BrainTrack Directory as Supplier of College Data 3Elsevier Selects BrainTrack Directory as Supplier of College Data 4
(Date:4/18/2014)... San Diego, Calif. (April 18, 2014) ― A new ... analyzing weekly patterns in health-related Google searches reveals ... public health strategies. , Investigators from San ... University, and the Monday Campaigns, analyzed "healthy" Google searches ... health-related, e.g., "healthy diet") originating in the U.S. from ...
(Date:4/17/2014)... The presence of chronic inflammation in benign ... prostate cancer, and this association was found even ... according to a study published in Cancer ... the American Association for Cancer Research. , An ... participants of the placebo arm of the Prostate ...
(Date:4/17/2014)... Scientists have identified new pain relief targets that ... pain. BBSRC-funded researchers at King,s College London made ... nerves in the periphery of the body. , ... and identifying mechanisms underlying pain generation and our ... related side effects." , One potential side effect ...
(Date:4/17/2014)... issue of Experimental Biology and Medicine ... Gaskins and Paul Kenis in the Institute of ... University of Illinois Urbana-Champaign describe their recent work ... a variety of cell functions including energy metabolism, ... roles in regulating normal cellular behavior, redox status ...
(Date:4/17/2014)... in the April issue of Immunity , Kevin ... Medical Research, says it,s time to take a fresh ... sepsis, which kills millions worldwide every year, including ... released into the bloodstream to fight an injury or ... for maintaining good health without inflammation, wounds and ...
Breaking Medicine News(10 mins):Health News:New research shows people are thinking about their health early in the week 2Health News:Chronic inflammation may be linked to aggressive prostate cancer 2Health News:Chronic inflammation may be linked to aggressive prostate cancer 3Health News:New pain relief targets discovered 2Health News:Live cell imaging reveals distinct alterations of subcellular glutathione potentials 2Health News:Feinstein Institute researcher publishes new perspective on sepsis 2
... IDXX ), announced today that its Board of ... additional four million,shares of its common stock under its ... open market or in negotiated transactions.,These shares are in ... 2007, under a previous Board authorization. The timing and,amount ...
... Consumer,Healthcare, a division of Wyeth (NYSE: WYE ... named Executive Vice President, Global Research and,Development (R&D), ... the consumer division,s global R&D organization. In her ... R&D efforts to,effectively bring new products to market ...
... Researchers find chronic worry impairs immune response to cancer-causing ... levels of daily stress could explain why some women ... cervical cancer, a new study suggests. , Scientists ... women, all diagnosed with cervical dysplasia (precancerous cervical lesions), ...
... Precious Medicare Dollars on Trial Lawyers and,Focus on Needy ... Blunt (Mo.) today praised President Bush,s proposal that would ... is clear that without substantial reforms, Medicare will not ... The legislation put,forth by the president is the needed ...
... million in bonuses and incentives, ADA, Mich., Feb. ... $1.072 billion, the fifth consecutive year in which the,company ... from the previous year,s sales of $1.12 billion, which ... affected minimally by actions the company took to,terminate the ...
... media outreach for TRIA, the first hair removal ... to enter U.S. home-based beauty device market, NEW ... Rpr Marketing Communications as its U.S. agency of record ... U.S. home-based beauty,device market., SpectraGenics, Inc. is a ...
Cached Medicine News:Health News:Wyeth Consumer Healthcare Names New Head of Global R&D 2Health News:Daily Stress May Raise Women's Risk of Cervical Cancer 2Health News:Daily Stress May Raise Women's Risk of Cervical Cancer 3Health News:Blunt Praises President's Plan to Save Medicare 2Health News:Quixtar Announces Fifth Consecutive Year of Billion-Dollar Sales 2Health News:Spectragenics Names Rpr Marketing Communications Agency of Record 2
Microforceps : Eckardt End & Side Gripping Forceps...
Blunt tipped forceps wlth a small grasping platform on each tip. For grasping fine membranes or grasping membranes adherent to the retinal surface....
Microforceps: Spaid Pic Forceps...
Blunt tipped forceps with small, slightly pointed grasping platforms on each tip. For general purpose (fine) membrane grasping and grasping membranes adherent to the retlnal surface....
Medicine Products: